Pfizer
PFIZER INC
Key figures
Period Jan 2025 to Dec 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$62.6B
Operating marginCalculated
Could not be retrieved
Net assets to total assetsCalculated
41.5%
Company profile
Tables scroll sideways
Disclosed data
Profitability
Could not be retrieved
Growth (revenue, 4-year average)
★☆☆☆☆position among all companies
-6.3%
Capital efficiency
★★☆☆☆position among all companies
9.0%
Revenue and profit
Performance, financial position and capital allocation
Pfizer
Recent performance trends
Pfizer
Cash flow trends
Consolidated indicators (8 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$81.3 billion | US$101.2 billion | US$59.6 billion | US$63.6 billion | US$62.6 billion |
| Net income | US$22.0 billion | US$31.4 billion | US$2.1 billion | US$8.0 billion | US$7.8 billion |
| Total assets | US$181.5 billion | US$197.2 billion | US$226.5 billion | US$213.4 billion | US$208.2 billion |
| Shareholders' equity | US$77.2 billion | US$95.7 billion | US$89.0 billion | US$88.2 billion | US$86.5 billion |
| Net cash provided by (used in) operating activities | US$32.6 billion | US$29.3 billion | US$8.7 billion | US$12.7 billion | US$11.7 billion |
| Net cash provided by (used in) investing activities | US$-22.5 billion | US$-15.8 billion | US$-32.3 billion | US$2.7 billion | US$-1.4 billion |
| Net cash provided by (used in) financing activities | US$-9.8 billion | US$-14.8 billion | US$26.1 billion | US$-17.1 billion | US$-10.3 billion |
| Cash and cash equivalents | US$1.9 billion | US$0.4 billion | US$2.9 billion | US$1.0 billion | US$1.1 billion |
Revenue scale in the same industry
Pfizer
Chemicals and pharmaceuticals: 56 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Johnson & JohnsonFY Dec 2025 US$94.2B
- 2 Procter & GambleFY Jun 2026 US$87.0B
- 3 ELI Lilly ANDFY Dec 2025 US$65.2B
- 4 Merck & CoFY Dec 2025 US$65.0B
- 5 PfizerThis companyFY Dec 2025 US$62.6B
- 6 AbbVieFY Dec 2025 US$61.2B
- 7 BRISTOL-MYERS SquibbFY Dec 2025 US$48.2B
- … 49 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$2.6 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$1.1 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$-10.3 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-1.4 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$11.7 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$6.6 billion | Consolidated | Disclosed |
| Stockholders' equity (including non-controlling interests) | US$86.8 billion | Consolidated | Disclosed |
| Non-controlling interests | US$0.3 billion | Consolidated | Disclosed |
| Net assets | US$86.5 billion | Consolidated | Disclosed |
| Net sales | US$62.6 billion | Consolidated | Disclosed |
| Net income | US$7.8 billion | Consolidated | Disclosed |
| Total assets | US$208.2 billion | Consolidated | Disclosed |
| Operating margin | Cannot be calculated | Not applicable | Not calculated (no operating income in this year's 10-K) |
| Net assets to total assets | 41.5% | Consolidated | Calculated |
| Net margin | 12.4% | Consolidated | Calculated |
| Return on equity | 9.0% | Consolidated | Calculated |